For the Inventor, By the Inventor

Enter assignee name

Biontech Se

USPTO Granted Patents = 69

CIPO Patents = 11

EPO Patents = 31

Trademarks = 29

Forward Citations = 48

Loading Chart...

Loading Chart...

142 inventors (with patents filed for the assignee):

Ugur Sahin (55 out of 185 patents)

Friederike Gieseke (13 out of 17 patents)

David Satijn (12 out of 41 patents)

4. Paul Parren (11 out of 127 patents)

5. Isil Altintas (11 out of 16 patents)

6. Alexander Muik (11 out of 11 patents)

7. Heinrich Haas (10 out of 20 patents)

8. Mustafa Diken (10 out of 17 patents)

9. Sebastian Kreiter (9 out of 23 patents)

10. Rik Rademaker (7 out of 27 patents)

11. Andreas Kuhn (7 out of 10 patents)

12. Kerstin Walzer (6 out of 7 patents)

13. Tim Beissert (6 out of 12 patents)

14. Sebastian Hörner (5 out of 5 patents)

15. Annette Vogel (5 out of 5 patents)

Core Competencies:

RNA Therapeutics

Immunogenicity Reduction

Liposomal RNA Formulations

Tumor Antigens

Cytotoxic Immunostimulating Particles

Coronavirus Vaccines

Monoclonal Antibodies

Bispecific Antibodies

In Vitro Transcription Technologies

Immune Response Stimulation

RNA Constructs

Cancer Immunotherapy

69 patents: Sort by Forward Citations

1. 12522640 - IL2 Agonists (2026-01-13),

2. 12516333 - 3'-UTR SEQUENCES FOR STABILIZATION OF RNA (2026-01-06),

3. 12516104 - Compositions and Methods for Diagnosis and Treatment of Cancer (2026-01-06),

4. 12460198 - Method for reducing immunogenicity of RNA (2025-11-04),

5. 12433911 - Preparation and storage of liposomal RNA formulations suitable for therapy (2025-10-07),

6. 12421319 - Binding agents that bind OX40 (CD134) and method of use thereof to treat disease (2025-09-23),

7. 12419965 - RNA particles comprising polysarcosine (2025-09-23),

8. 12410258 - Antibodies capable of binding to OX40, variants thereof and uses thereof (2025-09-09),

9. 12410221 - Tumor antigens for determining cancer therapy (2025-09-09),

10. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),

11. 12385049 - Modification of RNA, producing an increased transcript stability and translation efficiency (2025-08-12),

12. 12378531 - Use of RNA for reprogramming somatic cells (2025-08-05),

13. 12361554 - Systems and methods for segmentation and measurement of a skin abnormality (2025-07-15),

14. 12346849 - System for supporting teamwork by means of augmented reality (2025-07-01),

15. 12338448 - Trans-replicating RNA (2025-06-24),

BioNTech SE is a German biotechnology company that specializes in the development and manufacture of immunotherapies for the treatment of cancer and other diseases. Founded in 2008, BioNTech has emerged as a leading provider of innovative precision medicine for personalized cancer immunotherapy. The company combines cutting-edge technologies such as mRNA therapy and individualized neoepitope-targeting vaccines to develop novel treatment approaches. BioNTech is committed to revolutionizing the treatment of cancer and aims to achieve long-lasting, durable remissions for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

69 Patents

#6 in Mainz

#868 in Germany

#10,504 in the World

Biontech Se

Forward Citations = 48

142 inventors:

Ugur Sahin (55 out of 185 patents)

Friederike Gieseke (13 out of 17 patents)

David Satijn (12 out of 41 patents)

4. Paul Parren (11 out of 127 patents)

5. Isil Altintas (11 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…